| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Revance Therapeutics, Inc.$3.65
0 (0%)
C 48Pipeline Score Undervalued Biotech · Clinical
Market Cap
379.98 M
EPS
-1.92
P/E Ratio
-
Value Trade
15.06 M
-0.55 %
Week
18.18 %
1 Month
-38.31 %
3 Month
-2.15 %
6 Month
-83.21 %
5 Year
-82.67 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
4.12 M
52 Week Range
2.30 - 7.56
% held by Insiders
0.09 %
% held by Institutions
0.87 %
Enterprise Value
682.26 M
Total Shares
104.39 M
Short %
0.05 %
Float Shares
91.29 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
C48
Pipeline Score $1.6B
Pipeline ValueUndervalued
Valuation Signal9
Drugs Scored4.2x
rNPV / MCap Top 73%
Micro Cap (rank 245 of 905)
Percentile RankRevance Therapeutics, Inc. carries a moderate pipeline score (48/100), with $5.6B risk-adjusted pipeline value, led by Botulinum Toxin Type A in Skin Aging (Phase 3), across $114B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Botulinum Toxin Type A Small molecule | Skin Aging | Phase 3 | NCT01940991 | 58% | $4.0B | COMPLETED | 779 | - | - | Nov 1, 2013 | - | Jan 31, 2014 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in RVNC
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Revance Therapeutics, Inc. (RVNC) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
RVNC
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
RVNC
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
RVNC
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
RVNC Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
RVNC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How RVNC ranks across every disease it competes inCompetitive Position is a premium feature
See how RVNC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial